Tobramycin inhalation powder versus Tobramycin inhalation solution for cystic fibrosis
Hernández-Vásquez A, Pichon-Riviere A, Augustovski F, Ciapponi A, García Martí S, Alcaraz A, Bardach A, López A, Rey-Ares L
Record ID 32016000894
Spanish
Authors' objectives:
To assess the available evidence on the efficacy, safety and coverage related aspects among different inhalation tobramycin formulations in patients with cystic fibrosis.
Cystic fibrosis (CF) is an autosomal recessive genetic disorder caused by a CFT (Cystic Fibrosis Transmembrane Conductance Regulator) gene disorder, affecting approximately 1 every 2,000-3,000 newborns in Europe and 1 every 3,500 newborns in the US. This disorder causes exocrine gland dysfunction, thus resulting in a significant inflammatory response in the airways, abnormal mucus, obstruction and tissue damage, favoring bacterial growth. Pseudomonas aeruginosa is one of the main colonizing pathogens and the most important cause of morbidity and mortality in this condition; therefore its eradication is very important to improve disease prognosis. Among the three routes of antibiotic administration (oral, inhalation and intravenous), inhalation is an attractive alternative for the treatment of lung infections, since it provides high local concentrations and it reduces systemic exposure.
Authors' recommendations:
There is moderate quality evidence, including a single study comparing both inhalation modes. No significant differences were found in clinically significant results between tobramycin inhalation solution and tobramycin inhalation powder. The clinical practice guidelines and coverage policies found do not consider tobramycin inhalation powder as a first line treatment and in some cases, they mention it as a treatment alternative only under certain conditions such as intolerance or no response to colistin solution, colistin powder or tobramycin inhalation solution; and with price reduction agreements that make tobramycin inhalation power more affordable.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Humans
- Cystic Fibrosis
- Pseudomonas Infections
- Pseudomonas aeruginosa
- Tobramycin
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.